Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation

Kidney International

Volumn 59, Issue 4, 2001, Pages 1264-1273

  Ni, X P ^a   Safai, M ^a   Gardner, D G ^a   Humphreys, M H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial natriuretic peptide; Chronic liver disease; GMP specific phosphodiesterase; Inner medullary collecting duct; Sodium excretion

Indexed keywords

1,3 DIMETHYL 6 (PROPOXY 5 METHANESULFONYLAMIDOPHENYL)PYRAZOL[3,4D]PYRIMIDIN 4(5H) ONE; ATRIAL NATRIURETIC FACTOR; CALCIUM; CALMODULIN; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SODIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CELL FREE SYSTEM; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; HORMONE RESISTANCE; HYDROLYSIS; IC 50; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY COLLECTING TUBULE; LIVER DISEASE; MALE; NATRIURESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SODIUM METABOLISM; SODIUM RETENTION; WESTERN BLOTTING;

EID: 0035067381     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590041264.x     Document Type: Article

References (32)

1. Atrial natriuretic peptide: Renal effects in cirrhosis of the liver
2. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome
3. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann nephritis
4. Mechanisms contributing to renal resistance to atrial natriueritic peptide in rats with common bile duct ligation
5. Identification and selective inhibition of four distinct soluble forms of cyclic nucleotide phosphodiesterase activity from kidney
6. Cyclic 3′,5′-nucleotide phosphodiesterases in dynamics of cAMP and cGMP in rat collecting duct cells
7. 1 cells
8. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure
9. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
10. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: Alternative splicing of mRNA transcripts, genomic structure and sequence
11. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
12. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
13. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
14. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
15. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor
16. Characterization of a novel potent and specific inhibitor of type V phosphodiesterase
17. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: In vitro and in vivo characterization
18. cGMP mediates effects of atrial peptides on medullary collecting duct cells
19. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5): cGMP versus cAMP substrate selectivity
20. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid
21. An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase
22. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: Identification and differential expression of immunologically distinct forms in the rat brain
23. Inhibition of phosphodiesterase isoenzymes and cell function by selective PDE5 inhibitors
24. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases
25. Neural control of renal function in edema-forming states
26. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats
27. Inhibition of cGMP-phosphodiesterase restores the glomerular effects of atrial natriuretic factor in low sodium diet rats
28. Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure
29. Regulation of renal glomerular and papillary ANP receptors in rats with experimental heart failure
30. Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus
31. Extrarenal resistance to atrial natriuretic peptide in rats with experimental nephrotic syndrome
32. Blunted effect of ANP on hematocrit and plasma volume in streptozotocin-induced diabetes mellitus in rats